EP1625843A1 - Dispositif de mamelon - Google Patents

Dispositif de mamelon Download PDF

Info

Publication number
EP1625843A1
EP1625843A1 EP04728413A EP04728413A EP1625843A1 EP 1625843 A1 EP1625843 A1 EP 1625843A1 EP 04728413 A EP04728413 A EP 04728413A EP 04728413 A EP04728413 A EP 04728413A EP 1625843 A1 EP1625843 A1 EP 1625843A1
Authority
EP
European Patent Office
Prior art keywords
nipple
drug
holding member
cap
container
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04728413A
Other languages
German (de)
English (en)
Other versions
EP1625843A4 (fr
Inventor
M. Minami-urawa techno-center Combi Corp INOUE
N Minami-urawa techno-center Combi Corp TAKAMIZU
T. Minami Corporation KAN
W. Combi Corporation BUKAWA
T. Combi Corporation WATANABE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Combi Corp
Original Assignee
Combi Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Combi Corp filed Critical Combi Corp
Publication of EP1625843A1 publication Critical patent/EP1625843A1/fr
Publication of EP1625843A4 publication Critical patent/EP1625843A4/fr
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J11/00—Teats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J17/00—Baby-comforters; Teething rings
    • A61J17/001—Baby-comforters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/0015—Devices specially adapted for taking medicines
    • A61J7/0053—Syringes, pipettes or oral dispensers

Definitions

  • the present invention relates to a nipple apparatus which can administrate drugs to babies.
  • comforters filled with drugs have been known as means for administrating drugs to babies while allowing them to enjoy the articles in their mouths (See, for example, TOKUHYOU No. 2001-511644).
  • a comforter has a mouthpiece with vacancies in which a tablet(s) is disposed. While a baby is enjoying such a comforter in its mouth, the tablet is administered on a time-release basis to the baby.
  • the tablet upon supplementing the tablet to the comforter, the tablet must be necessarily positioned in the vacancy of the mouthpiece, which makes the supplementary work cumbersome or complex.
  • comforter should be washed regularly, it is not possible to wash the comforter selectively because it is combined with a container into a single unit.
  • the present invention was made in the light of the above problems, and hence it is an object of this invention to provide a nipple apparatus for enabling to perform the drug supplement and washing with ease.
  • the present invention is a nipple apparatus comprising a nipple, a nipple holding member for holding the nipple, and a cap for engaging with the nipple holding member; wherein a drug container portion in which a drug is filled and which is covered with a film on its nipple side, is provided in the cap, and wherein a cutting portion for cutting the film when the cap engages with the nipple holding member is provided at the nipple holding member.
  • the present invention is a nipple apparatus, wherein a liquid permeating member extending into the nipple is provided at the nipple holding member, and the cutting portion comprises a projection for sticking the film.
  • the present invention is a nipple apparatus, wherein an external thread is formed in the nipple holding member and an internal thread for engaging with the external thread is formed in the cap.
  • the present invention is a nipple apparatus, wherein the liquid permeating member comprises a plate-like member for abutting with the film of the drug container portion and a rod-like member extending from the plate-like member toward the nipple.
  • the present invention is a nipple apparatus, wherein an opening is provided in the plate-like member of the liquid permeating member, and the projection projects from the nipple through the opening toward the drug container portion.
  • the present invention is a nipple apparatus, wherein the drug container portion comprises a drug container which is provided in the cap.
  • the present invention is a nipple apparatus, wherein the drug container portion comprises an area divided by the film in the cap.
  • the present invention is a nipple apparatus, wherein the nipple holding member has a communicating space in communication with the nipple, the communicating space being covered with a compartment wall which is provided on the side of the drug container portion and has a communicating port.
  • the present invention is a nipple apparatus, wherein the cutting portion of the nipple holding member comprises an edge portion of the compartment wall.
  • the present invention is a nipple apparatus comprising a one-way valve in the opening of the compartment wall for introducing the drug from the drug container portion to the needle holding member.
  • the present invention is a nipple apparatus comprising a nipple, a nipple holding member having a container housing portion communicating with the nipple, for holing the nipple, a cap attached swayably to the needle holding member and covering the container housing portion, wherein a drug container in which a drug is filled, having an opening on the side of the nipple is provided in the container housing portion.
  • the present invention is a nipple apparatus, wherein a cylindrical guide projecting toward the nipple is provided in the container housing portion, and the drug container has a spout inserted in the cylindrical guide.
  • the present invention is a nipple apparatus, wherein the drug container is removable from the container housing portion, and an engagement rib for engaging with the cylindrical guide of the container housing portion is provided in the cap.
  • the present invention is a nipple apparatus, wherein the drug container is formed of a flexible material and fixed in the container housing portion, and a pressing portion for crushing the drug container is provided in the cap.
  • the present invention is a nipple apparatus, wherein the drug is xylitol.
  • the present invention is a nipple apparatus, wherein the drug comprises a virus capturing composition.
  • the present invention is a nipple apparatus, wherein the virus capturing composition contains a water extract of swallow nests and/or an enzymatically-treated substance of swallow nests as an effective ingredient.
  • Figs 1 to 3 illustrate a first embodiment of a nipple apparatus according to the present invention.
  • Fig. 3 is a view taken along line III of Fig. 1.
  • a nipple apparatus 10 comprises a nipple 11 to be put in a mouth of a baby, a nipple holding member 15 for holding the nipple 11, a liquid permeating member 25 extending from the nipple holding member 15 into the nipple 11, and a cap 17 engaging with the nipple holding member 15.
  • drug container (drug container portion) 20 is provided, which is filled with a liquid-state drug containing, for example, a xylitol ingredient for preventing dental caries.
  • a surface on the side of nipple 11 of the drug container 20 is covered with a film 21 formed of a silver foil or resin.
  • a projection 19 for sticking the film 21 of the drug container 20 when the cap 17 engages with the nipple holding member 15, is provided in the needle holding member 15.
  • the projection 19 serves as a cutting portion for cutting the film 21 when the cap 17 engages with the nipple holding member 15.
  • the nipple 11 has a cylindrical nipple body 11 a and a plate-like proximal portion 11b provided at a proximal end of the nipple body 11 a.
  • an opening 12 is provided in the nipple body 11 a for supplying outward a drug which has been directed through the liquid permeating member 25.
  • the nipple holding member 15 has a cylindrical portion 15a, and a larger diameter portion 15b having a diameter lager than that of the cylindrical portion 15a.
  • the proximal portion 11 b of the nipple 11 is inserted in the larger diameter portion 15b of the nipple holding member 15, and a holding frame 13 is further fitted in the larger diameter portion 15b from the outside of the proximal portion 11 b. In such a manner, the nipple 11 is held by the nipple holding member 15.
  • the drug container 20 is so constructed that it is inserted in the cylindrical portion 15a of the nipple holding member 15, and the drug container 20 is fixed to the cap 17.
  • the nipple side surface of the drug container 20 is covered by the film 21 as mentioned above, and the film 21 is stuck and broken with ease by the projection 19 of the nipple holding member 15.
  • the liquid permeating member 25 has a disk-shaped and plate-like member 25b for abutting with the film 21 of the drug container 20, which is of the same shape as the film 21, and a rod-like member 25a extending from the plate-like member 25b toward the nipple 11.
  • the liquid permeating member 25 is made entirely of a sponge material and transmits a drug contained in the drug container 20 toward the nipple 11.
  • an opening 26 is formed, locating below the rod-like member 25a.
  • the rod-like member 25a of the liquid permeating member 25 is preferably of the same outer surface shape as the inner surface shape of the nipple body 11a of the nipple 11: In such a case, the liquid permeating member 25 can be positioned and fixed by the nipple body 11 a.
  • the projection 19 of the nipple holding member 15 is positioned between the cylindrical portion 15a and the larger diameter portion 15b, and has a pointed distal end on the side of the film 21 of the drug container 20.
  • An external thread 16 is formed in the outer surface of the cylindrical portion 15a of the nipple holding member 15, while an internal thread 18 for engaging with the external thread 16 is provided in the inner surface of the cap 17. Rather than the thread engagement, the cylindrical portion 15a and the cap 17 may engage with each other in a one-touch fitting manner.
  • the cylindrical portion 15a of the nipple holding member 15 and the cap 17 should be engaged in a hermetically sealed state.
  • the projection 19 of the nipple holding member 15 is inserted in the opening 26 of the plate-like member 25b of the liquid permeating member 25.
  • proximal portion 11 b of the nipple 11 is then fitted in the larger diameter portion 15b of the nipple holding member 15, and the holding frame 13 is in turn fitted in the larger diameter portion 15b thereby to hold the nipple 11 by using the nipple holding member 15.
  • a sealing material is located between the larger diameter portion 15b of the nipple holding member 15 and the holding frame 13.
  • the external thread 16 of the nipple holding member 15 and the internal thread 18 of the cap 17 engage with each other, and the cap 17 is fitted around the cylindrical portion 15a of the nipple holding member 15.
  • the drug container 20 is already attached to the inner surface of the cap 17, and upon fitting the cap 17 around the cylindrical portion 15a of the nipple holding member 15, the film 21 of the drug container 20 is stuck and broken by the projection 19 of the nipple holding member 15.
  • a liquid-state drug (including a xylitol ingredient) in the drug container 20 travels through the liquid permeating member 25 toward the nipple 11.
  • the drug having traveled toward the nipple 11 through the liquid permeating member 25 is then directed from the opening 12 of the nipple body 11a into the mouth of the baby, thereby performing the prevention of dental caries utilizing the xylitol ingredient.
  • cap 17 and drug container 20 can be removed from the nipple holding member 15, and a new cap 17 having a pre-loaded drug container 20 can be attached to that nipple holding member 15.
  • each component can be disassembled in a reverse manner to the above described procedure so as to wash it separately (See Fig. 2).
  • a second embodiment of the nipple apparatus according to the present invention will be described with reference to Figs. 4 and 5.
  • like parts to those of the first embodiment shown in Figs. 1 to 3 are denoted by like numerals, and thus their detailed descriptions are omitted.
  • a nipple apparatus 10 comprises a nipple 11 to be put in a mouth of a baby, a nipple holding member 15 for holding the nipple 11, and a cap 17 engaging with the nipple holding member 15.
  • a film 21 is provided in the cap 17.
  • a liquid-state drug for example, a liquid-state drug containing a xylitol ingredient for preventing dental caries.
  • the area 30 formed by the film 21 in the cap 17 constitutes a drug containing portion.
  • an edge portion (cutting portion) 15d of a compartment wall 15c which will be described below cuts and breaks the film 21.
  • the nipple holding member 15 includes a cylindrical portion 15a and a larger diameter portion 15b provided at one end of the cylindrical portion 15a, and the compartment wall 15c is provided at the other end of the cylindrical portion 15a.
  • the nipple holding member 15, which is constructed as described above, has a communicating space 33 therein in communication with the interior of the nipple. 11, and the space 33 is covered with the compartment wall 15c.
  • a communicating port 31 is formed in the compartment wall 15c, and an one-way valve 32 is attached to the surface on the side of the communicating space 33 of the compartment wall 15c for sealing the communicating port 31 so as to enable it to freely open and close.
  • the one-way valve 32 operates to introduce a drug in the area 30 into the communicating space 33, while it prevents the transfer of the drug from the communicating space 33 to the area 30.
  • the proximal portion 11 b of the nipple 11 is fitted in the larger diameter portion 15b of the nipple holding member 15, and the holding frame 13 is then fitted in the larger diameter portion 15b thereby to hold the nipple 11 by using the nipple holding member 15.
  • An internal thread 18 of the cap 17 engages with an external thread 16 of the nipple holding member 15, and the cap 17 is fitted around the cylindrical portion 15a of the nipple holding member 15.
  • a drug is already filled in the area 30 divided by the film 21 in the cap 17, and when the cap 17 is fitted around the cylindrical portion 15a of the nipple holding member 15, the film 21 in the cap 17 is cut by the edge portion 15d of the compartment wall 15c of the nipple holding member 15.
  • the drug in the area 30 flows into the communicating space 33 of the nipple holding member 15 through the communicating port 31 and one-way valve 32, then the drug in the communicating space 33 travels toward the nipple 11.
  • the drug having traveled toward the nipple 11 is then directed from the opening 12 into the mouth of the baby, thereby enabling to prevent dental caries utilizing the xylitol ingredient.
  • cap 17 when all drug in the area 30 of the cap 17 is consumed, the cap 17 can be removed from the nipple holding member 15, and a new cap 17 can be attached to the nipple holding member 15.
  • each component can be disassembled in a reverse manner to the above described procedure so as to wash it individually (See Fig. 5).
  • the supplement work can be carried out with ease and simplicity, as well as each component can be disassembled for easy washing.
  • a nipple apparatus 10 comprises nipple 11 which is put in a mouth of a baby, nipple holding member 15 holding the nipple 11 and having container housing portion 43 in communication with the nipple 11, and cap 42 attached swayably to the container holding member 15 and covering the container housing portion 43.
  • the nipple is of a hollow shape, and is configured to store a liquid state drug, for example, a drug containing a xylitol ingredient for preventing dental caries, which is delivered into and fills drug container 45, as described below. Also in the nipple 11 is provided an opening 12 for supplying the drug stored in the interior outward.
  • a liquid state drug for example, a drug containing a xylitol ingredient for preventing dental caries, which is delivered into and fills drug container 45, as described below.
  • an opening 12 for supplying the drug stored in the interior outward.
  • the nipple holding member 15 includes flange 40 for holding the nipple 11, and flange cover 41 provided on the flange 40, and the container housing portion 43 is disposed in the flange cover 41.
  • the container housing portion 43 provided in the flange cover 41, is open at its upper portion, and a drug container 45 containing a liquid state drug is housed in the container housing portion 43. Also in the container housing portion 43 is provided cylindrical guide 44 for projecting toward the nipple 11, where the container housing portion 43 is in communication with the nipple 11 through the cylindrical guide 44.
  • the cap 42 is attached swayably to the flange cover 41 of the nipple holding member 15 through a pivot shaft 42a and is configured to cover the container housing portion 43 from above.
  • an engagement rib 48 for engaging with an upper end of the cylindrical guide 44 is attached to an inner surface of the cap 42.
  • the upper end of the cylindrical guide 44 has a tapered shape becoming narrower as one moves downward, and distal portion 48a of the engagement rib 48 is also of a tapered shape becoming narrower downward corresponding to the upper end of the cylindrical guide 44.
  • the engagement rib 48 is preferably formed of a flexible material.
  • a drug in a liquid state is filled in the interior of the drug container 45, and it is housed in the container housing portion 43.
  • the drug container 45 is formed of a flexible material, and has a container body 45a for containing the drug, and a spout 46 formed of a hard material and disposed at a lower portion of the container body 45a.
  • the spout 46 of the drug container 45 has an external thread 46a formed in its outer surface, and the spout 46 is inserted and fixed in the cylindrical guide 44 of the nipple holding member 15 by screwing the external thread 46a into an internal thread of the cylindrical guide 44 (not shown).
  • the spout 46 may be fitted in the cylindrical guide 44 without forming the external thread on the outer surface of the spout 46.
  • a cover 47 screwed into the spout 46 of the drug container 45 is first removed, and the external 46a of the spout 46 of the drug container 45 is then screwed into the internal thread of the cylindrical guide 45.
  • the drug container 45 can be fixed firmly in the container housing portion 43.
  • the container body 45a formed of a flexible material of the drug container 45 is urged to be pressed downwardly from the above to supply the drug contained in the container body 45a into the nipple 11 through the spout 46 and cylindrical guide 44.
  • the drug container 45 is then removed from the container housing portion 43, and the cap 42 pivots about the pivot shaft 42a to close the container housing portion 43 with the cap 42.
  • the engagement rib 48 provided on the inner surface of the cap 42 engages with the upper end of the cylindrical guide 44 to seal securely the upper end of the cylindrical guide 44.
  • the engagement rib 48 is formed entirely of a flexible material, it can be assured that the upper end of the cylindrical guide 44 is sealed hermetically by the distal portion 48a of the engagement rib 48.
  • the drug in the nipple 11 travels from the opening 12 into the mouth of the baby, thus enabling to prevent dental caries utilizing the xylitol ingredient.
  • a drug container 45 is fixed to container housing portion 43.
  • the drug container 45 includes a container body 45a containing a drug and formed of a bellows-like flexible material, and a spout 46 provided at a lower end of the container body 45.
  • Nipple holding member 15 for holding the nipple 11 has a flange 40 and a container housing member 43 provided on the flange 40.
  • the container housing portion 43 is configured to house the drug container 45 therein, and cylindrical guide 44 to be narrower toward the nipple 11 is provided under the container housing portion 43.
  • the container housing portion 43 is open at its upper portion, and cap 42 for covering the housing portion 43 is pivotally attached thereto.
  • a pressing portion 49 for pressing the bellows-like container body 45a is provided on the inner surface of the cap 42.
  • the drug container 45 is housed in the container housing portion 43 of the nipple holding member 15, while the spout 46 of the drug container 45 is inserted into the cylindrical guide 44.
  • the spout 46 can be fixed into the cylindrical guide 44 to securely fix the drug container 45 in the container housing portion 43.
  • the cap 42 pivots to cover the container housing portion 43 therewith.
  • the container body 45a of the drug container 45 is pressed by the pressing portion 49 of the cap 42, and the drug contained in the container body 45a is directed toward the nipple 11 through the outlet port 46 and cylindrical guide 44.
  • a drug container 45 includes a container body 45a filled with a drug and a spout 46 provided at a lower end of the container body 45a.
  • the container body 45a does not have a bellows-like configuration, but has a shallow chamber-like shape, and is formed of a flexible material.
  • the drug container 45 is housed in container housing portion 43 of nipple holding member 15. Again, with an external thread formed in the outlet port 46 of the drug container 45 and with an internal thread formed in the cylindrical guide 44, the spout 46 may be screwed into the cylindrical guide 44.
  • the cap 42 pivots to cover the container housing portion 43 therewith, causing the pressing portion 49 to press the container body 45a of the drug container 45.
  • the drug in the container body 45 can be directed toward the nipple 11 through the outlet port 46 and cylindrical guide 44.
  • Figs. 10 to 12 is different only in the point of using a virus capturing composition in place of the drug containing a xylitol ingredient as a liquid state drug, but it is substantially the same as the embodiments illustrated in Figs. 1 to 9 in the other features.
  • the drug container 30 shown in Figs. 1 to 3 is filled with a drug containing a virus capturing composition in place of a xylitol ingredient
  • the area 30 of the cap 17 shown in Figs. 4 and 5 is filled with a drug containing a virus capturing composition in place of a xylitol ingredient
  • the drug container illustrated in Figs. 6 to 9 is filled with a drug containing a virus capturing composition in place of a xylitol ingredient.
  • This virus capturing composition contains a water extract of swallow nests and/or an enzymatically-treated substance of swallow nests as an effective ingredient.
  • the swallow nest is a nest fabricated by cave swallows using their saliva formed in a thread-like material.
  • the nest has been utilized as a high class food material from old times, and also used as a food providing various medical effects, such as healing of the pulmonary disease, enhancement of the stomach activity, expectorant effect, skin rejuvenation, nutrient and sthenia.
  • Ingredients of this material include proteins and carbohydrates, but little lipids.
  • the swallow nests that are commercially available include those harvested in natural caves (cave nests) and those cultured in the interior (house nests), and both of them can be used. These materials are of various types including those produced only by removing dirt, such as feather and droppings, from the swallow nests and washing them, and those made by collecting debris of the swallow nest, repeating bleach and wash, and shaping the treated materials. It is preferred, however, to use swallow nests not subjected to excessive wash and bleach in their pretreatment.
  • the water extract of swallow nests used in the present invention can be obtained in the following procedure.
  • the filtrate can be used, directly or otherwise properly concentrated into a concentrate, as the virus capturing composition to be used in the present invention.
  • these materials can be freeze-dried or spray-dried.
  • the enzymatically-treated substance of swallow nests can be obtained by preparing an extract liquid (pre-filtered solution) by adding to the swallow nest ground to the same particle size as described above water or hot water of 10 to 1,000 times the mass of the particles and extracting the admixture in the same manner as above, and thereafter subjecting the so-obtained extract liquid, a filtrate obtained by filtration of the extract liquid or a solution obtained by heating the extract liquid at 60 to 130°C for 5 to 30 minutes to an enzymatic process.
  • an extract liquid pre-filtered solution
  • the enzyme is preferably protease, and generally, those commercially marketed as enzymes for foods can be used in combination of one or two types or more of them.
  • these enzymes can include "Pancreatine F” (trade name, produced by Amano Seiyaku Co., Ltd.), "Aloaze AP-10” (trade name, produced by Yakult Yakuhin Kogyo Co. Ltd.), “Papain Soluble” (trade name, produced by Yakult Yakuhin Kogyo Co., Ltd.), and "Heat Resistive Protease Thermoaze” (trade name, Yamato Kasei Co., Ltd.).
  • the enzymatic process condition is not specified in particular, provided that a suitable amount of an enzyme or enzymes is added at a pH of the solution being adjusted to one suitable for the enzyme(s) to be used, allowing the enzymes to react at a suitable temperature for them for 0.5 to 24 hours, then devitalizing the enzymes by a heat treatment or the like.
  • the filtrate obtained by filtrating the reaction liquid can be used, directly or properly concentrated into a concentrate, as the virus capturing composition to be used in the present invention. Alternatively, these materials can be freeze-dried or spray-dried.
  • the average molecular weight of the enzymatically processed material is preferably within a range of 500 to 200,000, more preferably within a range of 2,000 to 70,000.
  • the virus capturing composition used in the present invention can include functional food materials, such as saccharides, lactic acid bacteria, bifidus bacteria, polyphenol, oligosaccharide; proteins, aliphatic acids, minerals, vitamins, dietary fibers, sugar alcohols, surfactants, and preservatives.
  • functional food materials such as saccharides, lactic acid bacteria, bifidus bacteria, polyphenol, oligosaccharide; proteins, aliphatic acids, minerals, vitamins, dietary fibers, sugar alcohols, surfactants, and preservatives.
  • the form of the virus capturing composition is not critical, but is preferably in a form of solution or jelly. It is also contemplated that the virus capturing composition has highly established safety due to its food-derived ingredients, and therefore it can be used directly for a human body as an inhalation agent.
  • the content of the water extract of swallow nests and/or the enzymatically-treated substance of swallow nests in the virus capturing composition is preferably in a range of 0.1 to 10,000 ⁇ g/mL, and more preferably in a range of 0.2 to 400 ⁇ g/mL.
  • Table 1 Sample Grade Treatment Method Sialic Acid Content (Total) Protein Content 1 Special Grade Protease treatment (37°C, 16 hours), followed by heating (90°C) devitalization. Filtration, followed by lyophilization. 7.6 % by weight 64.4 % by weight 2 First Grade Protease treatment (37°C, 16 hours), followed by heating (90°C) devitalization. Filtration, followed by lyophilization. 4.2 % by weight 67.8 % by weight 3 Second Grade Boiling after immersion in water, protease treatment (37°C, 16 hours), followed by heating (90°C) devitalization. Filtration, followed by lyophilization.
  • LDH lactic acid dehydorogenase
  • Each medium, EMEM (Eagles Minimum Essential Medium), including influenza viruses (A/PR/8/34 (H1N1) or A/Aichi/2/68 (H3N2)) of about 100 TCID 50 (50% Tissue-Culture Infection Dose) and each sample (ultimate concentration: 1 - 5000 ⁇ g/mL) shown in Table 1 were seeded to monolayer-cultured MDCK cells in a 96-well titer plate (flat bottom), and cultured at 34.5°C for 5 hours.
  • EMEM Eagles Minimum Essential Medium
  • influenza viruses A/PR/8/34 (H1N1) or A/Aichi/2/68 (H3N2)
  • TCID 50 50% Tissue-Culture Infection Dose
  • the liquid portion was removed, and the residue was suspended in 100 ⁇ L of the same medium. Further, the suspension was cultured at 34.5°C for 20 hours, and 12.5 ⁇ L of the so-obtained culture medium was diluted four fold with 100mM Tris hydrochloric acid buffer (pH 8.2), and then 50 ⁇ L of an reaction liquid (2mM NAD, 200m-unit/mL diaphorase, 190mM lithium lactate, 0.78mM nitro bluetetrazolium, 100mM Tris hydrochloric acid buffer (pH 8.2)) was added. After incubation at 37°C for 10 minutes, 100 ⁇ L of 0.5M hydrochloric acid was added to stop the reaction.
  • 100mM Tris hydrochloric acid buffer pH 8.2
  • the absorbance at 550nm (control: 630nm) was measured to obtain LDH activity.
  • Fetuin was used as a positive control.
  • Fetuin is an ingredient contained in fetal bovine serum, and is known to have influenza neutralizing activity. The results are shown in Fig. 10.
  • IC 50 for human influenza viruses (A/PR/8/34 (H1N1) and A/Aichi/2/68 (H3N2)) of sample 1 was 80 ⁇ g/mL, exhibiting an inhibition activity twice to eight times stronger than that of Fetuin as a positive control.
  • Sample 2 was found to have an inhibition activity for the human influenza virus (A/PR/8/34 (H1N1)), which is substantially the same as Fetuin.
  • an EMEM medium containing a swallow nest solution (initial concentration: 5mg/mL) diluted twice with MDCK monolayer cells was added to MDCK cells having been monolayer-cultured in the 96-well titer plate (flat bottom), and the admixture was incubated at 37°C for 25 hours.
  • Investigation for cytotoxicity by measuring the activity of lactic acid dehydorogenase (LDH) in the obtained culture medium showed that the cytotoxicity to the MDCK cells was not exhibited in all of the samples, guaranteeing highly established safety.
  • LDH lactic acid dehydorogenase
  • a 25 ⁇ L aliquot of PBS was poured into each well of a 96-well titer plate (U-shaped bottom), and 25 ⁇ L of test samples (samples 1, 2) were added into the first row of the titer plate, and aspiration and discharge were conducted several times using a micropipette.
  • the 25 ⁇ L in the wells of the first row was then transferred to the second row, and aspiration and discharge were conducted several times using a micropipette. This manipulation was further repeated to the third row and then to the forth row to prepare rows diluted twice respectively.
  • Sample 1 was found to exhibit erythrocyte inhibition activities at very low concentrations against viruses among the tested influenza viruses (viruses isolated from humans, birds or swine) but for A/Swine/Colorado/1/77 (H3N2).
  • Sample 2 was found to exhibit erythrocyte inhibition activities at significantly low concentrations against viruses except for A/Memphis/1/71 and A/Swine/Colorado/1/77 (H3N2).
  • influenza viruses can recognize particular sugar chains including sialic acids and bind them.
  • the molecular species of sialic acids and their contents in the swallow nest were investigated using the following methods (See Hara, S., Yamaguchi, M., Takemori, Y., Nakamura, M., Ohkura, Y.: Highly sensitive determination of N-acetyl- and N-glycolylneuraminic acid in human serum and urine and rat serum by reverse d-phase liquid chromatography with fluorescence detection. J.
  • any of Sample 1 and Sample 2 was found to contain sialic acids in which N-acetylneuraminic acid (NeuAc) is a major molecular species. Less in the proportion, however, N-glycolylneuraminic acid (NeuGc) is also contained.
  • the content of N-acetylneuraminic acid of Sample 1 (12.25 %) is about twice higher than that of Sample 2 (6.52 %), and the content of N-glycolylneuraminic acid is 0.41 % in Sample 1, while 0.09 % in Sample 2.
  • sialic acids contained in Samples 1, 2 are quite similar to the sialic acid molecular species of humans, thus suggesting that proteins, peptides or lipid molecules containing such sialic acids may be ingredients for binding influenza viruses.
  • Sample 1 or Sample 2 dissolved in PBS was diluted with an equivalent amount of a buffer (2% SDS, 10% glycerin, 0.001% Bromphenol Blue, containing 0.0625M Tris buffer, pH 6.8) for preparing specimens used for the SDS-PAGE.
  • a buffer 2% SDS, 10% glycerin, 0.001% Bromphenol Blue, containing 0.0625M Tris buffer, pH 6.8
  • SDS-PAGE plate trade name "ET-1020L", Ato Co., Ltd.
  • the glycopeptides developed in the gel were transferred to a polyvinylidene difluoride (PVDF) film (produced by Daiichi Kagaku Co., Ltd.) (2mA/cm current flow for 30 minutes), and blocking was conducted at 4°C for 15 hours using a 5 % bovine serum albumin (BSA)-PBS solution (0.2 mL/cm). Washing the PVDF film with PBS five times, an influenza virus-0.25% BSA-PBS suspension adjusted to 2HAU was added to the film, which was then shaken gently at 4°C for 15 hours to avoid influence of virus-neuraminidase.
  • PVDF polyvinylidene difluoride
  • BSA bovine serum albumin
  • the PVDF film was then washed with PBS five times, and bonding of viruses was investigated using 10mL of 0.1M acetic acid (pH 6.0) with a coloring liquid (a mixture of 200 ⁇ L of an acetonitrile solution of 110mM 4-chloro-1-naphthol, 200 ⁇ L of an acetonitrile solution of 60mM N,N-diethyl-p-phenylenediamine-dihydrochloride, and 1 ⁇ L of a 31% hydroperoxide aqueous solution). The results are shown in Fig. 12.
  • any of Sample 1 and Sample 2 was identified to have bands (bands indicated by arrows in the drawing) bonding influenza viruses (A/Aichi/2/68 (H3N2), A/Memphis/1/71 (H3N2)).
  • bands bonding viruses could not be identified in a control experiment (Virus (-)) where the viruses were not added but other manipulations were conducted in the same manner as the samples, the identified bands were considered to be glycopeptides which can specifically bind the viruses.
  • the virus capturing composition of the present invention Since the virus capturing composition of the present invention has highly established safety due to its food-derived ingredients and has adsorption ability to various types of influenza viruses, it can be utilized as an infection preventing agent against viruses. In addition, by directing the virus capturing composition into a mouth of a baby through the nipple 11 of the nipple apparatus 10, virus infection of the baby can be prevented.
EP04728413A 2003-05-20 2004-04-20 Dispositif de mamelon Withdrawn EP1625843A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/JP2003/006286 WO2004103257A1 (fr) 2003-05-20 2003-05-20 Dispositif de tetine
PCT/JP2004/005628 WO2004103258A1 (fr) 2003-05-20 2004-04-20 Dispositif de mamelon

Publications (2)

Publication Number Publication Date
EP1625843A1 true EP1625843A1 (fr) 2006-02-15
EP1625843A4 EP1625843A4 (fr) 2008-01-23

Family

ID=33463130

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04728413A Withdrawn EP1625843A4 (fr) 2003-05-20 2004-04-20 Dispositif de mamelon

Country Status (6)

Country Link
EP (1) EP1625843A4 (fr)
JP (1) JP4472635B2 (fr)
KR (1) KR101128968B1 (fr)
CN (1) CN100418505C (fr)
AU (1) AU2003234839A1 (fr)
WO (2) WO2004103257A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020139183A1 (fr) * 2018-12-27 2020-07-02 Vivolab Ab Tétine pourvue d'un passage de fluide et d'un logement échangeable
WO2021256975A1 (fr) 2020-06-15 2021-12-23 Vivolab Ab Sucette
WO2021256976A1 (fr) * 2020-06-15 2021-12-23 Vivolab Ab Sucette

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT506295B1 (de) * 2008-07-23 2009-08-15 Mam Babyartikel Schnuller mit einem sauger
US8545439B2 (en) * 2009-03-10 2013-10-01 Dongguan Kidsme Industrial Limited Feeding apparatus

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2246555A (en) * 1990-07-19 1992-02-05 Christopher George Packaging for medicine
US5123915A (en) * 1990-04-27 1992-06-23 Miller Lawrence E Medicated pacifier
WO1998025572A1 (fr) * 1996-12-11 1998-06-18 Crowe D E Sucette pour nourrisson - unite d'administration de fluide

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA956606A (en) * 1970-02-02 1974-10-22 Stanley J. Koll Infant feeding package
JPH06508Y2 (ja) * 1987-03-05 1994-01-05 パシフイツクコンサルタンツ株式会社 割れにくく飛び散らないデザインタイル
JPH0423669U (fr) * 1990-06-19 1992-02-26
CN2115113U (zh) * 1992-02-14 1992-09-09 任超忠 两用幼儿喂药器
JPH065637U (ja) * 1992-06-30 1994-01-25 鴻明 李 服薬器
GB2309966A (en) * 1996-02-07 1997-08-13 Harwill Ind Pty Ltd Teat device for administering medicaments
JPH09226848A (ja) * 1996-02-22 1997-09-02 Nissho Corp 乳児用飲料容器
JP4233074B2 (ja) * 2000-04-24 2009-03-04 ピジョン株式会社 人工乳首
JP4023669B2 (ja) * 2001-10-23 2007-12-19 日本碍子株式会社 電気化学装置

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5123915A (en) * 1990-04-27 1992-06-23 Miller Lawrence E Medicated pacifier
GB2246555A (en) * 1990-07-19 1992-02-05 Christopher George Packaging for medicine
WO1998025572A1 (fr) * 1996-12-11 1998-06-18 Crowe D E Sucette pour nourrisson - unite d'administration de fluide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2004103258A1 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020139183A1 (fr) * 2018-12-27 2020-07-02 Vivolab Ab Tétine pourvue d'un passage de fluide et d'un logement échangeable
WO2021256975A1 (fr) 2020-06-15 2021-12-23 Vivolab Ab Sucette
WO2021256976A1 (fr) * 2020-06-15 2021-12-23 Vivolab Ab Sucette

Also Published As

Publication number Publication date
CN100418505C (zh) 2008-09-17
WO2004103257A1 (fr) 2004-12-02
JPWO2004103258A1 (ja) 2006-07-20
JP4472635B2 (ja) 2010-06-02
EP1625843A4 (fr) 2008-01-23
WO2004103258A1 (fr) 2004-12-02
KR20060010779A (ko) 2006-02-02
AU2003234839A1 (en) 2004-12-13
KR101128968B1 (ko) 2012-03-27
CN1791374A (zh) 2006-06-21

Similar Documents

Publication Publication Date Title
US20070021782A1 (en) Nipple device
JP5188631B2 (ja) インスリンを補った乳児用調製乳
WO2004035096A1 (fr) Composition possedant des proprietes oxydoreductrices stabilisees et procede de stabilisation de proprietes oxydoreductrices
EA005579B1 (ru) Пептиды, полученные из казеина, и их применение в терапии
BG98332A (bg) Полипептиди на вируса на хепатит с (нсv)
CN101262881A (zh) 通过交叉β结构的佐剂化
ES2707376T3 (es) Composición farmacéutica que contiene una mezcla de proenzimas y enzimas
EP1625843A1 (fr) Dispositif de mamelon
ES2627960T3 (es) Péptido derivado de lactoferrina humana para su uso como agente de enmascaramiento de antígenos
ES2252478T3 (es) Composiciones para la remocion del cerumen humano.
KR101987754B1 (ko) 구강 질환 검사용 용기 및 이를 포함하는 검사 키트
JP2005206547A (ja) ウイルス捕捉組成物、及びそれを吸着させたウイルス捕捉フィルター
Greene et al. A microbiological method for the determination of tryptophane
CN102488898B (zh) 龋齿疫苗及制备方法
TWI343813B (fr)
JP6903774B2 (ja) 経口送達のための安定なプールされた母乳抗体
WO2018073628A1 (fr) Dispositif d'échantillonnage non invasif de salive
CN103789254A (zh) 昆虫、昆虫血淋巴及其组装活性物和应用
WO1997037636A1 (fr) Lutte contre des microbes nocifs: therapie et prevention
CN1618405A (zh) 一种收集鼻咽细胞和分泌物用于诊断病毒性上呼吸道感染和筛查鼻咽癌的方法
RU2415419C1 (ru) Способ оценки активности препаратов, полученных из дождевых червей
RU2331437C1 (ru) Способ получения аллергена из клещей домашней пыли рода дерматофагоидес
BRPI0611973A2 (pt) matéria alimentìcia à base de lisozima
Bellido et al. Adverse reaction to sodium metabisulfite from fresh fish.
Khalaf et al. Immunotoxicity following pre-and post-natal aluminum exposure in rats

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051128

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20071220

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090206